Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AFFYMETRIX (AFFX) -- Ignore unavailable to you. Want to Upgrade?

To: John Starks who wrote (943)	8/4/1999 8:01:00 PM
From: LLCF	Respond to of 1728

<academic credentials of incy aside, do you agree that affy is marketing their chips more effectively to academic researchers? > INCY doesn't sell chips... experiments are sent to them and they send data back at this point in time. Notice this user quotes costs "per experiment": Message 10814009 Also, the lawsuit has made INCY a non-player so far as I can tell. DAK

To: John Starks who wrote (943)	8/5/1999 1:03:00 AM
From: jpbrody	Read Replies (1) \| Respond to of 1728

John, I do agree that affy is marketing their chips more effectively to academic researchers. I've heard of plenty of people using or thinking about using Affymetrix chips, but only one person using or the Incyte/Synteni chips in the academic world. I have also heard people talking about the idea of reusing the chips. You should only have to heat the things up to undo the hybridization and wash the sample off. Unfortunately, no one (that I know of) has developed the protocol to do so for the Affymetrix chips. The only people I know of using them have only used one or two chips. It would probably take 10 or so to get it down (the protocol) right. Certainly Affymetrix won't be publishing the protocol. In the case of Incyte/Synteni style chips the incremental cost per chip isn't that large, so it's not really worth the time to try and reuse it. Since we make are own, there's plenty of them around. By the way, from what I've heard Affymetrix isn't making a lot of money in the academic market. Supposedly the costs of supporting the various scientists are too high and chip volumes too low. I think they'd prefer dealing with big pharma. Jim